HomePress-release

Redding, California - July 15, 2024

Asia-Pacific Continuous Bioprocessing Market to be Worth $181.1 Million by 2030

Asia-Pacific Continuous Bioprocessing Market by Product (Filtration, Chromatography, Centrifuges, Consumables), Application (Commercial {Vaccines, Monoclonal Antibodies}, R&D), End User (Pharmaceuticals, Biotechnology, CROs) - Forecast to 2030

Meticulous Research– a leading global market research company, published a research report titled “Asia-Pacific Continuous Bioprocessing Market by Product (Filtration, Chromatography, Centrifuges, Consumables), Application (Commercial {Vaccines, Monoclonal Antibodies}, R&D), and End User (Pharmaceuticals, Biotechnology, CROs) - Forecast to 2030”.

According to this latest publication from Meticulous Research, the Asia-Pacific continuous bioprocessing market is expected to grow at a CAGR of 28.9% from 2024 to reach $181.1 million by 2030. The growth of this market is attributed to factors such as the emerging landscape of biopharmaceuticals in Asian countries, rising manufacturing and research-related outsourcing of biopharmaceuticals, expansions in CDMOs, developments in bioprocessing technologies, and growing partnerships and collaborations among market players for biopharma manufacturing. Furthermore, the shift towards bioprocessing 4.0 and the rising adoption of personalized medicines are expected to provide significant market growth opportunities.

However, the limitations of continuous bioprocessing may restrain the growth of this market. Additionally, manufacturers’ hesitation to shift from batch manufacturing to continuous manufacturing poses challenges to the market players.

Key Players:

The key players operating in Asia-Pacific continuous bioprocessing market are 3M Company (U.S.), Cytiva (U.S.), Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Sartorius AG (Germany), Repligen Corporation (U.S.), Eppendorf AG (Germany), Applikon Biotechnology (Netherlands), Pall Corporation (U.S.), Solida Biotech GmBH (Germany), Electrolab Biotech Limited (U.K.), Biowest (France), and Bionet (U.S.).

Asia-Pacific Continuous Bioprocessing Market: Future Outlook

Asia-Pacific continuous bioprocessing market is segmented by Product (Filtration Systems and Consumables, Chromatography Systems and Consumables, Cell Culture Media, Buffers, and Reagents, Incubators and Shakers, Bioreactors, Centrifuges, Sterilizers, and Other Instruments and Consumables), Application (Commercial Applications [Monoclonal Antibodies (mAbs) Production, Cell and Gene Therapy Production, Vaccine Manufacturing, Plasma Fractionation, and Recombinant Protein Production], R&D), End User (Pharmaceutical and Biotechnology Companies, Contract Development and Manufacturing Organizations (CDMOS) and Contract Research Organizations (CROS), and Academic and Research Institutes), and Country. The study also evaluates industry competitors and analyzes the market at the country level.

In 2024, among the products, the filtration systems and consumables segment is estimated to account for the largest share of the market. Filtration is commonly used in biopharmaceutical processing for separating components. It is used in various downstream operations, such as clarification, filtration of intermediates, critical final filling applications, or upstream processing for sterilizing-grade filtration of cell culture media. The highest revenue share of this segment is attributed to the recurring use of filtration at every step in bioprocessing and technological advancements in filtration technologies.

In 2024, among the applications, the commercial applications segment is estimated to account for the largest share of the market. Growing initiatives supporting the adoption of biopharmaceuticals, rising biopharmaceutical manufacturing outsourcing, and accelerated developments in personalized therapies are likely to enhance the demand for bioprocessing systems and consumables for the commercial bioproduction of monoclonal antibodies (mAbs), vaccines, gene therapies, and recombinant protein-based therapies; thereby drive the continuous bioprocessing market for commercial application.

In 2024, among the end users, the pharmaceutical and biotechnology companies segment is estimated to account for the largest market share due to factors such as capacity expansions by biopharmaceutical manufacturers and the extensive adoption of biopharmaceutical processing equipment for bioproduction in the biopharmaceutical and biotechnology sectors.

Geographic Review:

This research report provides a comprehensive analysis of the continuous bioprocessing market in Asia-Pacific (China, India, Japan, Singapore, South Korea, Australia, New Zealand, Indonesia, and Rest of Asia-Pacific). In 2024, China is expected to account for the largest share of the Asia-Pacific continuous bioprocessing market. The growing focus on the pharmaceutical and biopharmaceutical industry, rising investment in biosimilars, and support initiatives for CDMOs are the factors driving the market growth.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5682

Key questions answered in the report:

Which are the high-growth market segments in terms of product, application, end user, and country?
What was the historical market for continuous bioprocessing across Asia-Pacific?
What are the market forecasts and estimates for the period 2024–2030?
What are the major drivers, restraints, opportunities, and challenges in the Asia-Pacific continuous bioprocessing market?
Who are the major players in the Asia-Pacific continuous bioprocessing market?
How is the competitive landscape, and who are the market leaders in the Asia-Pacific continuous bioprocessing market?
What are the recent developments in the Asia-Pacific continuous bioprocessing market?
What are the different strategies adopted by the major players in the Asia-Pacific continuous bioprocessing market?
What are the geographical trends and high-growth countries?

Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research

3D Printing

5G Technology

Advanced Chemical & Materials

Agrochemicals

Algae Products

Alternative Proteins

Animal Health

Artificial Intelligence

Automotive Technologies

Big Data Analytics

Climate Technologies

Edible Insects

Electric Vehicle

Food & Agriculture Technologies

Hydrogen Technologies

Internet Of Things

In Vitro Diagnostics

Laboratory Instrumentation

Language Learning Technologies

Medical Technologies

Next Generation Technologies

Processing & Packaging Technologies

Robotics & Automation

Smart Technologies

Water & Wastewater Technologies

Miscellaneous / Others

Redding, California - July 15, 2024

Asia-Pacific Continuous Bioprocessing Market to be Worth $181.1 Million by 2030

Asia-Pacific Continuous Bioprocessing Market by Product (Filtration, Chromatography, Centrifuges, Consumables), Application (Commercial {Vaccines, Monoclonal Antibodies}, R&D), End User (Pharmaceuticals, Biotechnology, CROs) - Forecast to 2030

Recommended Readings

Advanced Chemical &
Materials

Food & Agriculture
Technologies

Next Generation
Technologies

Processing & Packaging
Technologies

Water & Wastewater
Technologies